Advertisement

Annals of Surgical Oncology

, Volume 20, Supplement 3, pp 509–516 | Cite as

Expression of Brachyury Gene Is a Significant Prognostic Factor for Primary Lung Carcinoma

  • Akira Haro
  • Tokujiro Yano
  • Mikihiro Kohno
  • Tsukihisa Yoshida
  • Takaomi Koga
  • Tatsuro Okamoto
  • Mitsuhiro Takenoyama
  • Yoshihiko Maehara
Translational Research and Biomarkers

Abstract

Background

The clinical significance of Brachyury expression and its relationship to epithelial–mesenchymal transition in primary lung carcinoma is unclear.

Methods

Expression of Brachyury mRNA was investigated in 104 surgically resected primary lung carcinoma tissues. Immunohistochemical analysis of Brachyury transcription factor, Slug, E-cadherin, IL-8, N-cadherin, and Ki67 was performed in 67 of 104 cases, and their expression was correlated to prognoses and clinicopathological factors.

Results

Brachyury mRNA expression in primary lung carcinoma tissues was a significant predictor of poor prognosis for 5-year disease-free survival and overall survival rates and was significantly correlated to vascular invasion, lymphatic permeation, histological grade, pathologic T stage, and pathologic N stage (P < 0.05). Brachyury mRNA expression was significantly inversely correlated to E-cadherin expression (P = 0.0252) and positively correlated to IL-8 protein (P = 0.0241) and to Slug protein (P = 0.0243) in adenocarcinoma tissues.

Conclusions

A positive association between Brachyury and Slug and IL-8, and a negative association with E-cadherin may lead to invasiveness and metastasis in primary lung carcinoma. Brachyury mRNA expression is a significant predictor of poor prognosis in primary lung carcinoma.

Keywords

Squamous Cell Carcinoma Normal Lung Tissue Lung Squamous Cell Carcinoma Lung Adenocarcinoma Cell Line Slug Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The authors declare no conflict of interest.

Supplementary material

10434_2013_2914_MOESM1_ESM.doc (51 kb)
Supplementary material 1 (DOC 51 kb)
10434_2013_2914_MOESM2_ESM.tif (1.7 mb)
Supplementary material 2 (TIFF 1748 kb)
10434_2013_2914_MOESM3_ESM.tif (1.4 mb)
Supplementdlxary material 3 (TIFF 1393 kb)
10434_2013_2914_MOESM4_ESM.tif (1.4 mb)
Supplementary material 4 (TIFF 1394 kb)

References

  1. 1.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRefGoogle Scholar
  2. 2.
    Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non–small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006;59:790–800.PubMedCrossRefGoogle Scholar
  3. 3.
    Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997;277:225–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Radisky ES, Radisky DC. Matrix metalloproteinase–induced epithelial–mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:201–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Xu J, Rodriguez D, Petitclerc E, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001;154:1069–79.PubMedCrossRefGoogle Scholar
  6. 6.
    Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial–mesenchymal transition of human carcinoma cells. Cancer Res. 2011;71:5296–306.PubMedCrossRefGoogle Scholar
  8. 8.
    Fernando RI, Litzinger M, Trono P, et al. The T-box transcription factor Brachyury promotes epithelial–mesenchymal transition in human tumor cells. J Clin Invest. 2010;120:533–44.PubMedCrossRefGoogle Scholar
  9. 9.
    Roselli M, Fernando RI, Guadagni F, et al. Brachyury, a driver of the epithelial–mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res. 2012;18:3868–79.Google Scholar
  10. 10.
    Palena C, Polev DE, Tsang KY, et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res. 2007;13:2471–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Kilic N, Feldhaus S, Kilic E, et al. Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer. 2011;47:1080–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Krukovskaia LL, Polev DE, Nosova Iu K, et al.[Investigation of transcription factor Brachyury (T) expression in human normal and tumor tissues] Vopr Onkol. 2008;54:739–43.PubMedGoogle Scholar
  13. 13.
    Park JC, Chae YK, Son CH, et al. Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochem Biophys Res Commun. 2008;365:221–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.PubMedCrossRefGoogle Scholar
  15. 15.
    Huber MA, Kraut N, Beug H. Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548–58.PubMedCrossRefGoogle Scholar
  16. 16.
    Storci G, Sansone P, Trere D, et al. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol. 2008;214:25–37.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhang K, Chen D, Jiao X, et al. Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling. Lab Invest. 2011;91:426–38.PubMedCrossRefGoogle Scholar
  18. 18.
    Shih JY, Tsai MF, Chang TH, et al. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res. 2005;11:8070–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Chou TY, Chen WC, Lee AC, et al. Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cell Signal. 2009;21:704–11.PubMedCrossRefGoogle Scholar
  20. 20.
    Cai M, Onoda K, Takao M, et al. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non–small cell lung cancer. Clin Cancer Res. 2002;8:1152–6.PubMedGoogle Scholar
  21. 21.
    Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11:573–87.PubMedCrossRefGoogle Scholar
  22. 22.
    Kubo F, Ueno S, Hiwatashi K, et al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol. 2005;12:800–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Bates RC, DeLeo MJ, 3rd, Mercurio AM. The epithelial–mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res. 2004;299:315–24.PubMedCrossRefGoogle Scholar
  24. 24.
    Kase S, Sugio K, Yamazaki K, et al. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000;6:4789–96.PubMedGoogle Scholar
  25. 25.
    Masuya D, Huang C, Liu D, et al. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer. 2001;92:2628–38.PubMedCrossRefGoogle Scholar
  26. 26.
    Chen JJ, Yao PL, Yuan A, et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003;9:729–37.PubMedGoogle Scholar
  27. 27.
    Orditura M, De Vita F, Catalano G, et al. Elevated serum levels of interleukin-8 in advanced non–small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res. 2002;22:1129–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Yuan A, Yang PC, Yu CJ, et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med. 2000;162:1957–63.PubMedCrossRefGoogle Scholar
  29. 29.
    Sobin L. TNM classification of malignant tumors. 6th rev ed. New York: Wiley-Liss, 2002.Google Scholar
  30. 30.
    Yuan A, Yu CJ, Luh KT, et al. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol. 2002;20:900–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Sanchez-Mora N, Presmanes MC, Monroy V, et al. Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. Hum Pathol. 2008;39:324–30.CrossRefGoogle Scholar
  33. 33.
    Moon KC, Cho SY, Lee HS, et al. Distinct expression patterns of E-cadherin and beta-catenin in signet ring cell carcinoma components of primary pulmonary adenocarcinoma. Arch Pathol Lab Med. 2006;130:1320–5.PubMedGoogle Scholar
  34. 34.
    Prudkin L, Liu DD, Ozburn NC, et al. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009;22:668–78.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Akira Haro
    • 1
  • Tokujiro Yano
    • 1
    • 2
  • Mikihiro Kohno
    • 1
  • Tsukihisa Yoshida
    • 1
  • Takaomi Koga
    • 3
  • Tatsuro Okamoto
    • 1
  • Mitsuhiro Takenoyama
    • 1
  • Yoshihiko Maehara
    • 1
  1. 1.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityKyushuJapan
  2. 2.Clinical Research InstituteNational Beppu Medical CenterBeppuJapan
  3. 3.Department of Pathology, Graduate School of Medical SciencesKyushu UniversityKyushuJapan

Personalised recommendations